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ABSTRACT 
AIM OF THE STUDY: 
                    Carcinoma breast is one of the most common cancer diagnosed and 
one of the most common cause of cancer related mortality. The aim of the study 
is to determine Incidence of Triple Negative Breast Cancer (TNBC) in Stanley, To 
analyze the ClinicoPathological features of Triple Negative breast cancer and to 
compare it with reports from other regions of the world. 
MATERIALS AND METHODOLOGY: 
           The material for our prospective study was conducted in Department Of 
General Surgery And Dept Of Medical Oncology in GOVERNMENT STANLEY 
MEDICAL COLLEGE AND HOSPITAL, CHENNAI 1, From October 2015 to September 
2016 (12months duration). ALL NEW CASES OF CARCINOMA BREAST Patients who 
attended Stanley Medical College for treatment were subjected to Trucut Biopsy.   
For all patients, the pathology was reviewed to confirm the diagnosis and the 
hormonal receptor and Her-2-neu status. We analyzed the clinicopathologic 
features of all triple negative cases which were diagnosed in this period. The TNM 
staging was based on clinical and radiological findings, Later all cases has been 
followed up for treatment details. 
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Discussion: 
           Incidence was very high (28%) in our study when compared to all others, 
mean age was 48.6yrs which is slightly lower when compared to Study done in 
mayo clinic(59.7yrs) Singapore(53yrs) Egyptian(52yrs). Premenopausal Status was 
lower (57.4%) when compared to Mulago(74%), Turkey(70%0), Bauer et al 
(64.6%) and it was slightly higher when compared to North India (52%) and 
Egyptians(48%).Parity more than 3 was lower (57.4%) when compared with North 
India study (71%). IDC is more common in our Study group (94%) along with Japan 
(95%), Singapore (93%) and Egyptian (93%). Grade 3 was more in all study groups 
highest in Japan (92%). Lymphovascular Invasion is also common (58%) in our 
study highest seen in North India (70%). Stage II with T2 lesion is more common in 
our Study (47%) which was lower when compared to other studies. Nodal spread 
(83%) and Metastasis (23%) is more common in our study when compared to 
other studies. 
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CONCLUSION: 
           Incidence rate Of Triple Negative Breast Cancer (TNBC) is higher in our 
Study, Affecting younger females with no significant risk factors or family history, 
Associated with significant poor prognostic factors like Nodal spread positivity, 
High grade tumor, IntraDuctal Carcinoma type, Lymphovascular invasion and 
metastasis. 
                     Therefore this study Shows TNBC is Very Aggressive tumor with 
increasing incidence rate among South Indian Population and this finding throws 
more light on the need for treatment strategies to be better tailored to effectively 
treat the TNBC patients. 
 
Keywords : Triple Negative Breast Cancer , Trucut biopsy, Premenopausal,  
IntraDuctal Carcinoma, Metastasis 
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                                          INTRODUCTION 
 
“ Incidence And ClinicoPathological Features of Triple Negative 
Receptors Status in Carcinoma Breast in Our Institution ” 
 
Breast cancer is the most common cancer among females in urban India and is 
rapidly catching up with cervical cancer in rural India(23).  An estimated  about 1 
Million cases of breast carcinoma has been diagnosed annually worldwide. Of 
these, more than 170,000cases are diagnosed as Triple-Negative. (15) 
 
Triple-Negative Breast Cancer (TNBC) is defined by the lack of protein expression 
of estrogen receptor (ER) and progesterone receptor (PR) and the absence of 
HER2 protein over expression. 
 
Triple-negative breast cancer (TNBC) accounts for approximately 15% of breast 
cancers.(21) 
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 TNBC is a Very aggressive tumour,  poor prognostic factor for disease-free and 
overall survival, 
 No effective specific targeted therapy is available for TNBC,  
 There is a clustering of TNBC cases in premenopausal women. 
 
The prevalence of TNBC is highest in premenopausal African American women; a 
recent report notes that 39% of all African American Premenopausal women 
diagnosed with breast cancer are diagnosed with TNBC. (16) 
 
Currently, effective treatment options are limited to chemotherapy, but the 
majority of patients who fail to achieve pathologic complete response after 
chemotherapy has unfavorable prognosis. 
 
Reliable data on TNBC in Indian setting is scarce(17) , hence, we felt the need to 
study the clinical profile of these cancers in our setting. 
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                                    AIMS & OBJECTIVES 
 
The aim of this study is to determine the 
1.  Incidence of Triple Negative Breast Cancer (TNBC) in Stanley, 
2. To analyze the ClinicoPathological features of Triple Negative breast cancer. 
3. To compare it with reports from other regions of the world. 
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REVIEW OF LITERATURE 
 
In 2007, Study Conducted in California TNBC affects younger, women with low 
SocioEconomicStatus. TNBC  were diagnosed at later stage and were more 
aggressive with poorer survival.(8) 
 
In 2009 Study conducted in Egypt concludes TNBC is more aggressive with IDC is 
most common along with 15%metastasis. (4) 
 
In 2010 study from Japan states that TNBC is very aggressive with poor 
pathological features like IDC (95%), grade3 (92%). Stage II (86.5%) is very 
common in TNBC. (6) 
 
In 2010, Study conducted in Singapore concludes that triple-negative breast 
cancers in an Asian population harbor adverse pathological features (IDC, grade3). 
(4) 
 
In 2010 mayo Clinic concludes TNBC associated with unique patient 
presentations, poor tumor characteristics. (7) 
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In 2012, According to study conducted at mulago hospital  States that there is a 
fairly high prevalence of triple negative breast cancer (20%) among Ugandan 
African women attending breast clinic at Mulago hospital and TNBC was found to 
be associated with poor prognostic characteristics. (12) 
  
In 2013 a study Conducted in North India showed Triple negative cancers are 
highly aggressive tumors that have distinct epidemiological, pathological and 
outcome characteristics. About 12.5% of breast cancers at this institute were 
TNBCs, and they affected younger females with no correlation between lymph 
node positivity and tumor size, had most of the recurrences distally in visceral 
organs within a period of 3 years. (14) 
 
In 2014 study from Kuwait concludes that TNBC is very aggressive, more common 
in premenopausal status, T2 lesion is more common with poor survival. (1) 
 
In Summary Review Of literature implies TNBC cases incidence increasing 
worldwide which are Very aggressive tumor  affecting younger age group of 
premenopausal  women along with poor pathologic features and high recurrence 
rate with poor survival.  
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EMBROYOLOGY 
 Mammary Gland  
• Modified apocrine sweat gland, Present in both males and females, In Female it 
serves for lactation; secondary sexual character. About 4% women have amazia. 
• Develops from the integument. 
 • Arises from the ventral surface of the embryo. (Milk line‐ thickened line of 
ectoderm).  
• Ducts and acini from ectoderm  
• Supporting tissue from mesenchyme.  
 
Milk line  
Milk line / Mammary ridge : Develops from base of fore limb (i.e.) Axilla to hind 
limb (i.e) groin. Except at the level of nipple, rest of it gets atrophied. 
 *Polythelia most common site 7‐10cm Below and medial to the nipple.  
• Development at  6th week of IU life - mammary ridge  
• Nipple develops ‐ ectoderm grows inward 15‐20 solid rods (rudimentary gland) 
and bulbous dilation at ends forms alveoli, At 5th month Intrauterine life cords 
develop 
21 
 
 • At 7/8th month - hollowing of ducts; differentiated as milk ducts; depression at 
site of nipple. 
 • At 9th month ‐ alveoli become canalised  
• At birth‐ mesenchyme proliferation and  nipple everts; areola becomes 
pigmented.  
• At puberty - 15‐20 lact ducts have 15‐20 lobules each. 
 • Witch’s milk - creamy white fluid because of circulating maternal estrogens 
 • Colostrum ‐ intial milk secreted. Rich in antibodies because of lymphocytes and 
plasma cells in the duct lining. Later stage replaced by milk high in lipid content. 
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ANATOMY 
Location  
• Situated in the anterior chest wall extending from 2nd to 6th rib and sternum to 
mid‐axillary line, surrounded by the superficial fascia; resting on the deep fascia 
overlying the pectoral fascia. 
The breast lies on the deep fascia covering the pectoralis major.  
• Still deeper there are 3 muscles –  
 Pectoralis major, Serratus anterior, External oblique muscle 
• It is separated from pectoral fascia by loose areolar tissue called Retro 
mammary space.   
    This allows the normal breast to move freely over the pectoralis major. 
 
The clavipectoral fascia envelops the pectoralis minor muscle and subclavius to 
attach to the clavicle , dividing into anterior and posterior lamina between the 
subclavius muscle. 
 
The costocoracoid membrane, a part of clavipectoral fascia is pierced by cephalic 
vein, thoracoacromial vessels, lymphatics and a branch of the lateral pectoral 
nerve. 
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The axilla is a pyramidal space with an apex, a base, anterior,posterior,medial and 
lateral walls. The apex is triangular in shape bordered by clavicle, scapula, and 
first rib,also called the cervicoaxillary canal. The base contains the axillary fascia 
beneath the skin . The anterior wall is composed of pectoralis major, pectoralis 
minor, subclavius and the clavipectoral fascia.The posterior wall consists of 
scapula, subscapularis, latissimus dorsi, and teres major .The medial wall is 
formed by lateral chest wall, second to sixth ribs, and serratus anterior . The 
lateral wall is formed by bicipital groove of humerus . 
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Suspensory ligaments of Astley Cooper: 
    Fibrous thickenings of supportive. 
   connective tissue interdigitate between the parenchymal tissue of the 
breast and extend from the deep layer of the superficial fascia to attach to 
the dermis of the skin. Develop from both ectoderm and mesoderm. 
Tail of Spence : 
      Prolongation from outer part of  gland which passes up to the level of 3rd rib in 
axilla where it is in contact with the main lymph glands of breast.    
This process of breast tissue gets into the axilla through an opening in the axillary 
fascia known as foramen of langer. 
 
Nipple and areola complex 
  Nipple - 4th ICS. It contains circular and longitudinal smooth muscle to 
make it stiff or flat.  
 It is pierced by 15 to 20 lactiferous ducts . 
 Each duct opens independently. 
 Has rich sensory nerve endings,  Supplied by 4th intercostal nerve  
 On Erection - serves milk  
 • Areola ‐ sebaceous/areolar glands,Pigmented .Has hypertrophied sweat glands 
(glands of Montomery) serves for protective lubrication during lactation. 
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 Ducts, acini‐>lobules‐>lobes‐> lactiferous ducts‐>lactiferous sinus‐>nipple. 
 
              
                                   This picture implies Nipple and areola complex 
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BLOOD SUPPLY 
 Arterial : 
 The blood supply of breast is from  internal thoracic artery, a branch of  1st part 
of subclavian artery which supplies medial aspect of breast (50%). 
 
The lateral part of the breast receives blood supply from  pectoral branches of 
thoracoacromial artery, lateral thoracic arteries a branch of Axillary artery , 
Lateral Perforator branch of posterior intercostal artery (supplies 2nd , 3rd 4th 
Intercoastal Spaces) and few unnamed branches (mammary branch ) from 
anterior intercostal artery.                                
                     
                           This Picture shows Blood supply of the Breast 
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Venous  Drainage 
Follows the arteries.  
• Internal mammary vein join subclavian vein.  
• Lat thoracic veins ‐> axillary vein  
• Lateral Perforater Branch Into Intercostal veins ‐> vertebral veins ‐> Vertebral 
plexus‐> Bone metastasis.  “BATSON’S PLEXUS” 
 
 
Nerve supply  
• It is innervated by 4‐6 th InterCostal nerve.( Ant and lateral cut Branches) 
 • Nipple ‐ T4 level ;  contains both autonomic nerve fibres and  sensory fibres. 
 
Lymphatic Drainage 
Is of great surgical importance  
• Arises in interlobular connective tissue and in walls of lactiferous ducts  
• Majority of breast drains into axillary LymphNodes.  
• 5groups: – Pectoral(anterior) – 75% – Subscapular(posterior) – Humeral(lateral) 
– Subclavicular(apical)  – Axillary (Central) 
 
28 
 
1.   The breast drains mainly to axillary lymph nodes– 75% 
•  Anterior  group  
            large glands situated along the lateral thoracic vein under the 
anterior axillary fold.  The axillary tail of spence is in actual contact with 
these glands.   
• Posterior  group  
        lie along the posterior axillary fold in relation to subscapular vessels. 
• Lateral group  
        along the upper part of the humerus in relation to the axillary vein. 
• Central  group 
       situated in the fat of upper part of axilla.  Enlargement of these glands, 
by pressure on the nerve cause intense pain in the distribution of nerve 
along the inner border of arm. 
• Apical group  
 also called infraclavicular glands.   
2. About 20% of lymph drains into the internal mammary nodes along internal 
thoracic vessels .  
3.  About 5% lymph drains into the posterior intercostal nodes 
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                       This picture shows five groups of axillary lymph nodes. 
 
BERG’S LEVELS OF AXILLARY NODES 
• LEVEL I   – Nodes located lateral to the pectoralis minor (anterior, posterior, 
lateral) 
• LEVEL II  –  Nodes  Behind the pectoralis minor (central) 
• LEVEL III – Nodes medial to pectoralis minor (apical) 
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Routes of Metastasis : 
 From medial lymphatics to parasternal nodes – Then to mediastinal nodes 
 Across the sternum in lymphatics to opposite side via cross‐mammary 
pathway – Then to contralateral breast  
  From subdiaphragmatic lymphatics to the nodes in abdomen – Then to 
liver, ovaries, peritoneum and other organs. 
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CARCINOMA BREAST:  
EPIDEMIOLOGY:  
• Carcinoma breast is one of the most common cancer diagnosed and one of 
the most common cause of cancer related mortality. The life time risk of 
developing cancer breast is approximately 1 in 8% to 1 in 12% and the risk 
of death from the disease in a persons lifetime is approximately 2.4%(18). 
1)Age shift 
2)Rising number of cases 
3)Late presentation 
4)Lack of awareness and screening 
  
RISK FACTORS:  
  HORMONAL 
• Increased exposure to estrogen 
• Factors that increase the number of menstrual cycles(early 
menarche,nulliparity,late menopause) 
• Exercise and longer lactation period are protective(factors that decrease 
the number of menstrual cycles are protective). 
• Older age at first live birth is also a risk factor. 
• Obesity increases the risk. 
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• OCP do not increase the risk. 
• Hormone replacement therapy in postmenopausal women increase the 
risk. 
 
NON HORMONAL : 
• Chest wall irradiation 
• Diet- eg.foods with high fat content 
• alcohol consumption 
• Sex-women are 100 times at a greater risk than men 
• Age-More common in 35 to 75 years of age. 
• History of breast cancer 
• Benign breast disease eg. Atypical ductal hyperplasia, Intraductal papilloma 
• Geographical-Disease of white western women 
• Genetic risk factors 
                a)BRCA 1 and 2 gene mutation 
                b)Cowden’s disease 
                c)Ataxia telengiectasia 
                d)Li-Fraumeni syndrome 
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BRCA gene 
Mechanism 
     Both BRCA genes are tumor suppressor genes that produce proteins that are 
used by the cell in an enzymatic pathway that makes very precise, perfectly 
matched repairs to DNA molecules that have double-stranded breaks. 
       
BRCA1: 
      Located in Chromosome17(17q21)long arm  with autosomal dominant trait 
with high penetrance, 90% chance for of breast cancer, 40% for ovarian cancer , 
using aHigh grade tumor, with negative receptor status , affecting younger age 
group, a higher prevalence of bilateral breast cancer. 
 BRCA2 : 
     Located in Chromosome 13q, autosomal dominant trait and has a high 
penetrance, Carrier 100-fold risk in male population ,IDC type ,with receptor 
status positive. 
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Histopathology Types of Breast Carcinoma  
On the basis of basement membrane invasion 
 CARCINOMA IN SITU  
DCIS (Ductal carcimoma in situ )  
            LCIS (Lobular carcinoma in situ) 
 INVASIVE  CARCINOMA  
 
DCIS 
• Proliferation of malignant mammary ductal epithelial cells without any 
invasion to basement membrane,Predominantly occurs in female breast.  
•  Accounts for 5% of male breast cancer 
 
DCIS is divided into  
 
• cribriform, papillary (Low grade) , Solid and Comedo (Highgrade) 
• 5times risk of developing into Invasive carcinoma 
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                                             Range of Ductal Carcinoma InSitu 
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      DUCTAL CARCINOMA IN SITU: COMEDO TYPE CENTRAL ZONE OF NECROSIS WITH CALCIFICATION  
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Lobular carcinoma in situ  
       From terminal duct lobular units, Occurs mostly in female breast  with Normal 
nuclear:cytoplasmic ratio. Approx, 20% will develop into invasive breast cancer 
within 15 years.  Pleomorphic variant - high of malignancy (potential) 
             
                    This picture shows  HPE of lobular Carcinoma in situ 
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Foot  and Stewart Classification For Invasive Breast Cancer  
I. Paget's disease of the nipple  
II. Invasive ductal carcinoma  
A. Adenocarcinoma 80%  
B. Medullary carcinoma 4%  
C. Mucinous (colloid) carcinoma 2%  
D. Papillary carcinoma 2%  
E. Tubular carcinoma (and ICC) 2%  
III. Invasive lobular carcinoma 10%  
IV. Rare cancers (adenoid cystic, squamous cell, apocrine) 
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IntraDuctal Carcinoma (IDC) 
Adenocarcinoma of the breast can be scirrhous, simplex, NST 
 INCIDENCE- 80%  
 AXILLARY LYMPH NODE METASTASIS- 60% 
 5th to 6th decade 
 TUMOR-firm to hard, irregular border, central streaks of chalky white 
stroma, foci of calcification 
 Well, modarate and poorly differentiated varieties  
 
 
                   
 
INFILTRATING DUCT CARCINOMA : ACCORDING TO GENE EXPRESSION PATTERN 
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                                    HPE picture of Invasive ductal Carcinoma 
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Invasive Lobular Carcinoma (ILC) 
• Incidence-10% 
• Bilateral and multicentric 
• Dyscohesive infiltrating cells in single file pattern 
• Signet ring cell-intra cytoplasmic mucin droplet 
                               
                                  HPE Picture of Invasive Lobular Carcinoma  
 
Mucinous carcinoma  
 Favourable  Prognosis, with good 10yr survival rate  80%  
66% of this type display hormone receptors.  
Nodal metastasis occurs (33%)  
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Medullary carcinoma  
      Accounts for 5 to 7% of breast cancer, Poor differentiation nuclei, a syncytial 
growth pattern,circumscribed border, lymphocyte and plasma cell intense 
infiltration, and little or no DCIS are the characteristic histological features of this 
type of tumor.  Prognosis is favorable;  however they have prognosis similar to 
that of invasive ductal carcinoma in case of mixed variants. 
    
                               
                                            Medullary Carcinoma HPE pattern 
 
•Tubular carcinoma  
Good prognosis with High survival rate, Breast conversative surgery can be done 
this type along with local irradiation, lymph nodal spread rare. 
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•Papillary carcinoma  
Better prognosis, low mitiotic,  70% cases were ER positive, very aggressive in 
case Invasive micropapillary ductal carcinoma. 
                                      Papillary breast Ca HPE pattern          
                     
 
INFLAMMATORY CARCINOMA 
 Most aggressive 
 Common in pregnancy and lactation 
 Mimics acute mastitis 
 Ductal or lobular type 
 Rapid metastasis  
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Pagets disease 
 Superficial manifestation of invasive or non invasive ductal carcinoma 
 Pagets cell with hyper chromatic nuclei and cytoplasmic halo 
 Crusted, scaly lesion, ulceration and destruction of nipple 
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CLINICAL FEATURES:  
      Physical examination must give due consideration to comfort and emotions of 
the patient. Careful inspection by patient in sitting position with arms by side and 
elevation. Nipple changes, any gross asymmetry or any lump or fullness were  
noted.  Then skin is inspected for any changes like dimpling , puckering, tethering 
and peau d'orange. Always the inframammary fold ,periclavicular regions should 
be inspected .Both axilla are then palpated. If palpable nodes are found their 
number, size, and mobility should be noted and axillary tail should also be 
palpated. 
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TRIPLE ASSESSMENT FOR DIAGNOSIS CA BREAST: 
  
CLINICAL EXAMINATION  
IMAGING (USG/MAMMOGRAM) 
PATHOLOGICAL (TRUCUT BIOPSY) 
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Mammography 
Indications 
 Screening mammography: Age >40 years. 
  Family h/o breast Ca or histological risk factor(early screening). 
  Diagnostic mammography: To evaluate the existing symptoms/features of 
breast disease. 
 Obese patients. Spread or denovo tumor of opposite breast. 
 Mastalgias, mammography guided biopsy.       
 Evaluation & followup in benign disease with high of malignant chance. 
 As Follow up in breast conservative surgery.  
  
              Microcalcifications                                          Spiculations 
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UltraSonaGram Breast 
Preferred in younger women . 
 
FEATURES: 
      To identity the lesion – whether it is solid or cystic, Size ,shape, margins of the 
lump, internal echoes, retro tumor acoustic shadowing, compressibility, Axillary 
nodes and for BIRADS staging. 
                      
                                 USG picture of Right Carcinoma Breast   
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     BIRADS STAGING             
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FNAC 
PROCEDURE: 
         Under sterile technique, a 23 gauge syringe needle taken.  
        Breast Lump held with two fingers, then needle is inserted into the lump,  by 
continuous negative pressure aspiration adequate material is collected sent for 
testing. 
                                         
 
Trucut Biopsy 
 Clear histological evidence and confirms DCIS 
 For tissue study instead of cellular in case of FNAC. 
 This allow proper neoadjuvant/primary chemotheraphy and receptor status 
of the tumor. (ER/PR/Her2Neu) 
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Investigations of Metastasis 
CHEST X RAY: 
           -Pleural effusion 
           -Cannon ball secondaries  
           -Mediastinal lymph nodes 
           -Secondaries in ribs 
X-RAY SPINE: 
          -Shows osteolytic secondaries  
RADIOISOTOPE BONE SCAN: 
     -To look for secondaries in bone in advanced cases 
MRI spine/pelvis: 
           -Osteolytic secondaries in vertebra & pelvis  
LUNGS:  CECT CHEST  
ABDOMEN: 
USG ABDOMEN: 
           -Liver secondaries. 
           - Ascites. 
           -‘krukenburg ’ tumor. 
CECT ABDOMEN: 
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Treatment Guidelines 
 
• EARLY BREAST CARCINOMA( I, IIA, IIB)  
               Breast conservative surgery/MRM  followed Chemotherapy  
 
• LOCALLY ADVANCED BREAST CARCINOMA(IIIa IIIb IIIc)  
         Neoadjuvant chemotherapy (down staging) Assess for Chemotheraphy 
response  followed  by Modified Radical Mastectomy (MRM) then Adjuvant 
Chemotherapy/radiotherapy  
 
• METASTATIC CARCINOMA (IV) 
              Hormone therapy, Chemotherapy/radiotherapy, Toilet Mastectomy  
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Modified Radical Mastectomy 
APPROACH : 
Horizontal elliptical incision of the breast with extension to the axilla  
Positioning 
 Arm abducted, Affected shoulder elevated slightly with flat pillow  
Incision: 
 Elliptical, Includes biopsy scar, Extended laterally for axillary clearance  
1. Positioning 
2. Incision 
3. Raising flaps 
4. Caudal dissection of the breast 
5. Cranial dissection of the breast 
6. Extension of the operation 
7. Removal at the axillary vein 
8. Resection of the pectoralis minor muscle ( Level I , II , III) 
Wound closure 
 Two suction drains 
 Subcutaneous sutures  
 Skin closure 
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Post Op care 
 Medical aftercare: Suction drain is removed from 2-5 days if the drain 
output is <30ml for 24 hours 
 Mobilization: Immediately mobilize the arm as far as the pain threshold 
allows. 
 Physiotherapy: Consider lymph drainage 
 Time off work: 2 weeks, depending on occupation and aftercare 
 Adjuvant chemotherapy 
 
  PALLIATIVE SURGERY - Locally advanced breast tumor or Metastatic breast c   
tumor with Fungating mass. 
  Tumour with breast tissue is removed to prevent further fungation. 
  Done after giving chemotherapy  
Indication of BCS 
• Lump < 4cm  
• N0, N1 (or) M0 
• Mammographically detected lesion 
• Well-differentiated tumor  
• Adequate sized breast to allow proper RT to breast  
• Breast of adequate size and volume 
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Contraindications  
• Tumour > 4cm  
• T4, N2 (or) M1  
• Family history/ BRCA1 & BRCA2 mutation carriers 
• Poorly differentiated tumor  
• Multicentric / Multifocal tumor  
• Central tumor  
• Tumour/breast size ratio is more (large tumor) 
• Connective tissue disorders 
• Extensive intraductal carcinoma  
• Collagen vascular disease 
Breast reconstruction surgery 
Reconstruction 
 Silicon gel implant 
 Saline implant 
 Prior tissue expansion- saline prosthesis 
 Musculocutaneous flap 
  LD flap 
  TRAM flap 
  DIEP flap 
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Prophylactic mastectomy 
 Patients with elevated risk (Genetic mutations, Known familial disease) 
 Most commonly bilateral mastectomies are done. 
Chemotheraphy 
 NEOADJUVANT  CHEMOTHERAPY 
     (Chemo Followed by Surgery) 
  ADJUVANT  CHEMOTHERAPY 
     (Surgery followed by Chemo) 
  PALLIATIVE CHEMOTHERAPY 
     (InOperable cases - Supportive care)  
Neoadjuvant 
 Administration of chemotherapeutic drugs in a large operable 
tumour to reduce the loco-regional tumour burden (down staging) to 
make it better amenable for surgery. 
 Usually 3 cycles are given pre operatively and  3 cycles are given 
postoperatively with 21 days interval.  
Adjuvant 
 Administration of  chemotherapeutic drugs after breast cancer surgery to 
eliminate clinically undetectable distant spread. 
  It is given in 6 cycles post operatively with 21 days gap. 
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CAF regimen 
  Cyclophosphamide  
  Adriamycin  
  5-fluorouracil  
CMF regimen  
  Cyclophosphamide 
  Methotrexate 
  5-fluorouracil          
PALLIATIVE   CHEMOTHERAPY  :    It is used in advanced and metastatic 
carcinoma breast.  
Hormonal therapy  
 Oestrogen receptor antagonists - Tamoxifen  
 Aromatase inhibitors - Letrozole,Aminoglutethimide  
 HER-2/Neu receptor blocker - Transtuzumab     
 LHRH antagonist - Goserelin  
 Progestogens - Medroxyprogesterone acetate 
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Transtuzumab 
• It is HER-2/Neu receptors blocker and prevents the growth of cancer cells. 
• It is useful only in HER-2/Neu positive patients. 
• Dosage: 4mg/kg as loading and 2mg/kg as maintenance for 1 year. 
• It has got cardiac side effects.  
Radiotherapy 
• Patient who undergo conservative breast surgery breast is irradiated after 
surgery. In atrophic scirrhous carcinoma as curative radiotherapy.In 
advanced tumour, radiation therapy is given when the tumour is fixed to 
chest wall. 
• In bone secondaries to palliate pain and swelling. 
• Tumour size more than 5cm 
• 4 or more positive nodes 
• Positive margins 
• Perinodal extension  
•  It is used in advanced and metastatic carcinoma breast.  
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MATERIALS AND METHODS 
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                                       MATERIALS AND METHODS 
PLACE OF STUDY: 
             Department Of General Surgery And Dept Of Medical Oncology in 
GOVERNMENT STANLEY MEDICAL COLLEGE  AND HOSPITAL, CHENNAI -1 
DURATION OF STUDY: 
          12 months  (October 2015 to September 2016) 
STUDY DESIGN: 
          PROSPECTIVE STUDY 
PATIENT SELECTION: 
          ALL NEW CASES OF CARCINOMA BREAST  
METHODOLOGY 
 Patients who attended Stanley Medical College , Chennai for  Admission, 
Investigation, Treatment of Breast cancer (New Cases)  
 Based on the Hospital Registry, Medical files of all patients diagnosed with 
Breast Cancer. 
 For all patients, Trucut Biopsy   Done  for  confirm diagnosis and Receptor status 
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TRUCUT BIOPSY 
 
 
Specimen sent to Pathology for  
 HPE Report (Grade and Type of Tumour) 
 ER/PR Status 
 Her 2neu Status 
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 ER, PR and Her2neu Receptors status are Assessed using 
Immunohistochemical Staining. 
 Negativity was defined as absent Immunohistochemical stain in all the 
examined tissue. 
 
The TNM staging was assessed based on clinical and radiologic findings. 
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Following Parameters are Analyzed in Triple Negative Breast Cancer : 
 Incidence Rate 
 In relation to Age 
 In relation to Parity  
 In relation to laterality 
 In relation to Family history breast cancer 
 In relation to PreMenopausal/PostMenopausal  
 In relation to TNM Staging  
 In relation to Grade and Type of Tumour  
 In relation to Metastasis at Diagnosis 
 In relation to lymphovascular invasion 
 In relation to chemotherapy 
 Comparison of Age with Grade of tumor 
 Comparison Of Nodal spread with Lymphovascular Invasion 
 Comparison of TNM Staging with Age and Menopausal status 
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RESULTS 
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         INCIDENCE RATE 
Incidence Rate 28.6 % 
 
     
 
In Our Study , the Incidence rate of Triple Negative breast Cancer is 28.6% 
Total number of Carcinoma Breast are 164 cases, in which Triple Negative 
Breast Cancer was  47 cases others 117 cases. 
 
 
Triple Negative 
29% 
Others 
71% 
Incidence of TNBC 
68 
 
AGE WISE  DISTRIBUTION 
 
 
 
 
 
 
 
In our study(total 47 cases), Almost more than 50% TNBC (27cases) comes under 
Age group of 41 to 60yrs, in which 19 cases out of 47 cases fall between 41 to 
50yrs 
0
5
10
15
20
25
30
Upto 40 yrs 41 - 60 yrs > 60 yrs
Agerange 
       AGE 
Distribution Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
 Upto40yrs 13 27.7 27.7 27.7 
41 - 60yrs 27 57.4 57.4 85.1 
> 60 yrs 7 14.9 14.9 100.0 
Total 47 100.0 100.0   
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FAMILY HISTORY OF BREAST CANCER: 
 
 
 
 
 
 
In our study Family history cancer was present in only 2 Cases (Total=47Cases) 
 
 
No 
96% 
Yes 
4% 
Family history of breast cancer 
 Family history      
  Of ca breast Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
 No 45 95.7 95.7 95.7 
Yes 2 4.3 4.3 100.0 
Total 47 100.0 100.0   
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IN RELATION TO PARITY     
                            
                          
 
 
 
 
 
 
In our study parity more than 3 (57.4%) was slightly common when compared to 
less than 3.   
 
Less than 3 
43% 
More than 3 
57% 
Parity 
                 Parity Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
 Less than 
3 
20 42.6 42.6 42.6 
More 
than 3 
27 57.4 57.4 100.0 
Total 47 100.0 100.0   
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MENOPAUSAL STATUS 
                 
  
                  
 
 
 
In our study group, Premenopausal status is more common (57.4%) when 
compared to post menopausal status which was 42.6% ( 20 cases) 
 
 
 
0
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10
15
20
25
30
Post Pre
Menopausal Status 
     Menopausal     
           status Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
 Post 20 42.6 42.6 42.6 
Pre 27 57.4 57.4 100.0 
Total 47 100.0 100.0   
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LATERALITY 
                   
 
 
                  
 
 
 
 This table Shows Triple Negative cases have Right side laterality (55.3%) slightly 
higher when to compared left side (44.7%) 
 
Left 
45% 
Right 
55% 
Laterality 
   Laterality Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
 Left 21 44.7 44.7 44.7 
Right 26 55.3 55.3 100.0 
Total 47 100.0 100.0   
73 
 
TYPE OF  TUMOUR 
                    
 
    In our study, IntraDuctal Carcinoma (IDC) is more common (93.6%) when 
compared to DCIS (4.3%) and Medullary Carcinoma (2.1%) 
 
0
10
20
30
40
50
DCIS IDC MEDULLARY
Type of tumour 
 Type of  Tumour Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
 DCIS 2 4.3 4.3 4.3 
IDC 44 93.6 93.6 97.9 
MEDULLARY 1 2.1 2.1 100.0 
Total 47 100.0 100.0   
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GRADE OF TUMOR 
                
                  
 
 
 
 
 
In Our Study group, Grade 3 (59.6%) tumor was more common followed by 
grade2 (34%). Grade 1 Tumour was very less (6.4%) 
 
0
5
10
15
20
25
30
Grade 1 Grade 2 Grade 3
Grade of tumour 
   Grade Of     
     Tumor Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
 Grade 1 3 6.4 6.4 6.4 
Grade 2 16 34.0 34.0 40.4 
Grade 3 28 59.6 59.6 100.0 
Total 47 100.0 100.0   
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NODAL SPREAD  
                    
 
 
 
 
               
In  Our study, Based on TNM Staging Nodal spread is more (83%) 39 cases. 
 
 
 
N0 
17% 
Others 
83% 
N staging 
 Nodal Spread Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
 N0 8 17.0 17.0 17.0 
Nodal (+) 39 83.0 83.0 100.0 
Total 47 100.0 100.0   
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TNM STAGING 
                       
                        
  
 
 
 
 
  
 In Our Study, Based on TNM Staging Stage IIB is more common (29.8%) followed 
by Stage IV (23.8%),  Stage IIIA (21.3%), Stage IIA (17%), Stage IIIB (8.5%). 
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8
10
12
14
16
IIA IIB IIIA IIIB IV
TNM Staging 
 TNM 
STAGING Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
 IIA 8 17.0 17.0 17.0 
IIB 14 29.8 29.8 46.8 
IIIA 10 21.3 21.3 68.1 
IIIB 4 8.5 8.5 76.6 
IV 11 23.4 23.4 100.0 
Total 47 100.0 100.0   
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EARLY BREAST CANCER:  
Picture on Right side is T2N1M0 lump in right  lower outer quadrant 
Picture on left side is  T2N0 M0 lump in right upper outer quadrant 
 
LOCALLY ADVANCED BREAST CANCER (LABC): 
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METASTASIS AT THE TIME OF  DIAGNOSIS 
                 
                      
                  
 
 
 
 
 
This table shows Metastasis (23.4%) is  common in Triple Negative ca breast cases 
in which bony metastasis was present in all cases followed by lung metastasis. 
17% 
6% 
2% 
75% 
Metastasis  at  Diagnosis 
BONE BONE, LUNG BONE, LUNG, LIVER NO
Metastasis at 
Diagnosis 
Frequen
cy Percent 
Valid 
Percent 
Cumulative 
Percent 
 BONE 8 14.9 14.9 14.9 
BONE, LUNG 3 6.4 6.4 21.3 
BONE, LUNG, 
LIVER 
1 2.1 2.1 23.4 
NO 35 76.6 76.6 100.0 
Total 47 100.0 100.0  
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TREATMENT DETAILS 
              
      Treatment     
        details Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
 Chemotherapy 8 19.1 19.1 19.1 
Modified radical 
mastectomy 
32 66.0 66.0 85.1 
Toilet mastectomy 3 6.4 6.4 91.5 
Lumpectomy/WLE 4 8.5 8.5 100.0 
Total 47 100.0 100.0   
 
 
In our study Majority cases underwent MRM 66% followed by palliative 
Chemotherapy 19.1%, Lumpectomy/Wide Local Excision (WLE) 8.5%, Toilet 
mastectomy 6.4% 
 
0 5 10 15 20 25 30 35
Chemotherapy
Modified radical masectomy
Toilet masectomy
Lumpectomy
Treatment Details 
80 
 
 
INTRA OP MRM - AXILLARY DISSECTION PICTURE SHOWING AXILLARY VEIN 
            
       MAHESWARI  50/F 1563894 RIGHT MRM  
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                                   POST OP WOUND AFTER MRM SURGERY 
                 
                    THAMARAI SELVI  48/F 1564796 RIGHT MRM POST OP WOUND 
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                                   RIGHT MODIFIED RADICAL MASTECTOMY SPECIMEN 
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      TOILET MASTECTOMY FOLLOWED BY SSG COVER FOR STAGE IV DISEASE 
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CHEMOTHERAPY                                                                     
 
       
 
 
 
 
 
This table shows  46.8% cases received Adjuvant Chemotherapy, 29.7% 
NeoAdjuvant  Chemotherapy, 23.5 % Palliative Chemotherapy. 
 
 
47% 
30% 
23% 
 CHEMOTHERAPY 
Adjuvant Neo adjuvant Palliation
 Chemotherapy Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
 Adjuvant 22 46.8 46.8 46.8 
Neo adjuvant 14 29.7 29.7 76.5 
Palliation 11 23.5 23.5 100.0 
Total 47 100.0 100.0   
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LYMPHOVASCULAR INVASION (LVI) 
                      
       
  
                         
 
 
 
This table shows Lympho Vascular invasion (LVI) is more common in patient who 
underwent MRM/Toilet Mastectomy (58%).  
 
42% 
58% 
LVI 
No Yes
Lymphovascular Invasion 
  Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
 No 19 41.1 42.2 42.2 
Yes 26 55.3 57.7 100.0 
Total 45 93.6 100.0   
 Others 2 6.4     
Total 47 100.0     
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AGE COMPARISON WITH TNM STAGING 
               
  
TNM Staging 
Total II       III IV 
Age range Upto 40 yrs Count 7 3 3 13 
 % of Total 14.9% 6.4% 6.4% 27.7% 
41 - 60 yrs Count 11 10 6 27 
 % of Total 23.4% 21.3% 12.8% 57.4% 
> 60 yrs Count 4 1 2 7 
 % of Total 8.5% 2.1% 4.3% 14.9% 
Total Count 22 14 11 47 
% of Total 46.8% 29.8% 23.4% 100.0% 
 
From above comparison of Age with TNM staging , Stage II is more common in all 
age groups 
 
0
2
4
6
8
10
12
Upto 40 yrs 41 - 60 yrs > 60 yrs
Agerange with Stage  
II III IV
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 STAGE COMPARISON WITH TUMOR GRADE 
                     
In Our study, Stage with Tumour Grade shows 
                    In Early breast Carcinoma Stage IIA (EBC) grade 1 is more common 
                    In Early Breast Carcinoma Stage II B (EBC) No Significant 
                    In all locally advanced Breast cancer Stage (LABC) Grade3  is common 
 
 
 
 
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
70.0%
IIA IIB IIIA IIIB IV
Stage with Grade of tumour 
Grade 1 Grade 2 Grade 3
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AGE COMPARISON WITH GRADE OF TUMOR 
                
    
Grade of tumor 
Total grade 1 grade 2 grade 3 
Age range Up to 40 
yrs 
Count 1 5 7 13 
 % of 
Total 
2.1% 10.6% 14.9% 27.7% 
41 - 60 
yrs 
Count 0 11 16 27 
 % of 
Total 
0.0% 23.4% 34.0% 57.4% 
> 60 yrs Count 2 0 5 7 
 % of 
Total 
4.3% 0.0% 10.6% 14.9% 
Total Count 3 16 28 47 
% of 
Total 
6.4% 34.0% 59.6% 100.0% 
 
 
                                         
 
 
 Grade 3 more common in all age group shows Significant p value  10.208 (<0.037) 
0
5
10
15
20
Upto 40 yrs 41 - 60 yrs > 60 yrs
Agerange with Grade of tumour 
Grade 1 Grade 2 Grade 3
Chi-Square Tests 
  Value df 
Asymp. Sig. (2-
sided) 
Pearson 
Chi-
Square 
10.208a 4 .037 
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GRADE COMPARISON WITH MENOPAUSAL STATUS 
                  
Chi-Square Tests 
  Value df 
Asymp. Sig. (2-
sided) 
Pearson Chi-
Square 
1.844a 4 .764 
 
There is no significant between grade of tumor and menopausal status 
Pvalve is 1.844  (< .764) 
 
0%
20%
40%
60%
80%
100%
Post Pre
Grade of tumour with Menopausal  
Grade 1 Grade 2 Grade 3
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NODAL SPREAD COMPARISON WITH MENOPAUSAL STATUS 
 
Chi-Square Tests 
  Value df Asymp. Sig. (2-sided) 
Pearson 
Chi-
Square 
1.539a 3 .673 
 
In Above Comparison there is no significant between Nodal spread with 
menopausal Status P valve is 1.539 (<0 .673) 
 
 
0
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20
Post Pre
N  with Menopausal 
N0 N1 N2 N3
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NODAL SPREAD COMPARISON WITH LVI 
 
 
In above Comparison there is significance between LVI positive in Nodal Spread 
cases. P valve is 10.518  (<0.015) 
0%
20%
40%
60%
80%
100%
No Yes
Nodes with LVI 
N0 N1 N2 N3
 
                             No                               Yes 
N0 38.9% 3.8% 
N1 61.1% 80.8% 
N2 0.0% 11.5% 
N3 0.0% 3.8% 
                                                      
   
 
 
 
Chi-Square Tests 
  Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 10.518a 3 .015 
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Discussion 
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DISCUSSION 
  Our study Incidence rate in Stanley Medical College was 28.6 % which was 
higher when compared to other studies 
 Most common age group is 40 to 50 yrs ( 19 cases out of 47) 
 Early age group is 30yrs and Older age group is 87 yrs. 
 Mean Age group is 48.6yrs 
 Family history breast cancer was seen in only 2 patients. 
 Parity more than 3 was slightly higher in TNBC. 
 TNBC is more common in Premenopausal Status (57.4%). 
 Nodal Spread is more common in TNBC (83%) 
 Grade 3 was more common in TNBC (59%) 
 IntraDuctal Carcinoma is more common in TNBC(94%) 
 Stage IIB is more common (29.6%) 
 Metastasis 23% where Bone is more common(15%)  
 Lymphovascular invasion is more common in TNBC (58%)  
  Adjuvant 47% NeoAdjuvant 30%  and Palliative chemotherapy 23% 
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CROSS COMPARISONS 
 Age with grade of tumor  
        Grade 3 more common in all age group Significant  p value <0.5 
 Lymphovascular invasion  with Nodal spread 
        80% nodal positivity has LVI Significant  p value  <0.15 
 Age with Stage 
         Stage II is common in all age groups 
 Menopausal status with TNM Staging 
         No significant  
 Menopausal status with grade of tumor 
         No significant 
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COMPARISON TABLES 
Patient characteristics in different studies. (table 1) 
 
In this Above table 1 Our study has been compared with various study groups 
done in various regions of world including North India. 
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Contd., (Table 1) Incidence was very high (28%) in our study when compared to all 
others, mean age was 48.6yrs which is slightly lower when compared to Study 
done in mayo clinic(59.7yrs) Singapore(53yrs) Egyptian(52yrs).  
Premenopausal Status was lower (57.4%) when compared to Mulago(74%), 
Turkey(70%0), Bauer et al (64.6%) and it was slightly higher when compared to 
NorthIndia ( 52%) and Egyptians(48%) 
Parity more than 3 was lower (57.4%) when compared with North India study 
(71%) 
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Tumor characteristics in TNBC in different studies (table 2) 
 
In above table 2 comparison IDC is More common in our Study group(94%) along 
with Japan(95%) Singapore(93%) and Egyptian(93%). Grade 3 was more in all 
study group highest in Japan (92%). Lymphovascular Invasion is also common 
(58%) in our study highest seen in NorthIndia(70%). Stage II with T2 lesion is more 
common in our Study(47%) which was lower when compared to other studies. 
Nodal spread (83%) and Metastasis(23%) is more common in our study when 
compared to other studies. 
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CONCLUSION 
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CONCLUSION 
                      Incidence rate Of Triple Negative Breast Cancer (TNBC) is higher in 
our Study, Affecting younger females with no significant risk factors or family 
history, Associated with significant poor prognostic factors like Nodal spread 
positivity, High grade tumor, IntraDuctal Carcinoma type, Lymphovascular 
invasion and metastasis. 
                     Therefore this study Shows TNBC is Very Aggressive tumor with 
increasing incidence rate among South Indian Population and this finding throws 
more light on the need for treatment strategies to be better tailored to effectively 
treat the TNBC patients. 
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                                                                PROFORMA 
 
NAME:                                                                                              BIOPSY NO: 
AGE/SEX: 
ADDRESS WITH CONTACT NUMBER: 
IP NO: 
DATE OF ADMISSION: 
DATE OF SURGERY: 
DATE OF DISCHARGE: 
HISTORY OF PRESENTING ILLNESS: 
 Lump Site: 
 Onset/Duration: 
 Progression: 
 Radiation/Type of Pain: 
 Skin Involvement: 
 
H/O Breast Lump : 
H/O Any Previous Breast Surgery/Procedure: 
Menstrual Status :  
      Married/Unmarried: 
      Premenopausal / Postmenopausal: 
      Parity : More Than 3/ Less Than 3/Nulliparous 
      Breastfeeding:  Up to 1yr/ Less Than 1yr 
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      Breast Feeding : Single/Both Breast 
H/O  Breast Cancer / Gynaecological Malignancy In Family: 
H/O  Hormone Replacement Therapy: 
 
CLINICAL EXAMINATION: 
GENERAL EXAMINATION: 
SYSTEMIC EXAMINATION: 
                 L/E: 
                CVS: 
                 RS: 
                 PER ABDOMEN: 
                 CNS: 
CLINICAL DIAGNOSIS WITH TNM STAGING: 
Investigations: 
 Routine Investigations [CBC, RFT, CXR ECG ] 
 FNAC And Trucut Biopsy  
 USG B/L Breast And Axilla And Usg Abd/Pelvis 
 CECT Chest/ Abdomen Pelvis (LABC) 
 Xray Of Lumbar Vertebra And Long Bones /Bone Scan (LABC) 
 
Final Diagnosis: 
Treatment: Surgery Followed By Adjuvant Chemotherapy/Neoadjuvant 
Chemotherapy/Toilet mastectomy / Palliative chemotherapy                  
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                         GOVT.STANLEY MEDICAL COLLEGE, CHENNAI- 600 001 
                                                 
                                                    INFORMED CONSENT 
 
 
                                                    DISSERTATION TOPIC:   
“Incidence And ClinicoPathological Features of Triple Negative Receptors Status in 
Carcinoma Breast  in Our Institution ” 
  
PLACE OF STUDY: GOVT. STANLEY MEDICAL COLLEGE, CHENNAI 
NAME AND ADDRESS OF PATIENT: 
 
 
 I, _____________________ have been informed about the details of the study in 
my own language. 
 
I have completely understood the details of the study. 
 
I am aware of the possible risks and benefits, while taking part in the study. 
 
I understand that I can withdraw from the study at any point of time and even 
then, I will continue to receive the medical treatment as usual. 
 
I understand that I will not get any payment for taking part in this study. 
 
I will not object if the results of this study are getting published in any medical 
journal, provided my personal identity is not revealed. 
 
I know what I am supposed to do by taking part in this study and I assure that I 
would extend my full co-operation for this study. 
 
 
 
 
 
 
Name and Address of the Volunteer:        Name and signature of investigator Date: 
              
 
 
Signature/Thumb impression of the Volunteer 
 
 
Date: 
 
 
Witnesses: (Signature, Name & Address) 
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              “Incidence of Triple Negative Receptors Status in Carcinoma Breast in Our 
Institution”      
 
நான் இந்த ஆராய்ச்ெியில் விவரங்கனை முற்றிலும் புாிந்து சகாண்டடன். 
ஆய்வில் பங்கு எடுத்துடபாது, ொத்தியமாை அபாயங்கள் மற்றும்பயன்கனை 
பற்றி நான் அறிந்துள்டைன். 
நான் எந்தசவாரு டவனையிலும் ஆய்வில் இருந்து திரும்ப முடியும், அதன் 
பின்ைர், நான் வழக்கம் டபால் மருத்துவெிகிச்னெ சபற முடியும் என்று புாிந்து 
சகாள்கிடறன் 
நான் ஆய்வில் பங்கு எடுத்து பணம் எனதயும் சபற முடியாது என்று 
அறிந்துள்டைன். 
இந்த ஆய்வின் முடிவுகள் எந்த சமடிக்கல் ஜர்ைலில் சவைியிடப்பட 
இருந்தால் நான் எதிர்க்கவில்னை ,என்தைிப்பட்ட அனடயாைத்னத 
சவைிப்படுத்தப்பட்டு இருக்ககூடாது. 
நான் இந்த ஆய்வில் பங்சகடுப்பதன் மூைம்  நான் என்ை செய்ய டபாகிடறன் 
என்று சதாியும் 
நான் இந்த ஆய்வில் என் முழு ஒத்துனழப்னபயும் சகாடுப்டபன் என்று 
உறுதியைிக்கிடறன். 
தன்ைார்வைர்       ொட்ெி  
சபயர் மற்றும் முகவாி     சபயர் மற்றும் முகவாி 
னகசயாப்பம் / விரல்டரனக:     னகசயாப்பம் / விரல்டரனக: 
 
ஆராய்ச்ெியாைராக னகசயாப்பம்மற்றும்டததி 
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111 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
112 
 
 
 
 
